Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 1 , Pages 26-30 , March 2007

Photodynamic therapy for prostate cancer: One urologist's perspective

References 

  1. Arnfield MR, Chapman JD, Tulip J, Fenning MC, McPhee MS. Optical properties of experimental prostate tumors in vivo. Photochem Photobiol. 1993;57(2):306–311
  2. Bonnett R, White RD, Winfield UJ, Berenbaum MI. Hydroporphyrins of the meso-tetra hydroxy phenyl porphyrin series as tumor photosensitizers. Biochem J. 1989;261(1):277–280
  3. Chang SC, Buenaccorsi G, MacRobert A, Bown SG. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra (m-hydroxy phenyl) chlorin. Lasers Surg Med. 1996;
  4. Chang SC, Buenaccorsi GA, MacRobert A, Bown SG. Interstitial photodynamic therapy in the canine prostate with disulphonated aluminum phthalocyanine and 5-aminolivulinic acid induced protoporphyrin IX. Prostate. 1997;32:89–98
  5. Chen B, Pogue BW, Hoopes PJ, Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Bio Phys. 2005;61(4):1216–1226
  6. Chen B, Zupko I, deWitte PA. Photodynamic therapy with hypericum in a mouse P38. Int J Oncol. 2001;18(4):737–742
  7. Chen Q, Wilson BC, Shetty SD, Patterson MS, Cerny JC, Hetzel FW. Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. Radiat Res. 1997;147:86–91
  8. Dole KC, Chen Q, Hetzel FW, Whalen LR, Huang Z. Effects of photodynamic therapy on peripheral nerve: in situ compound-action potentials study in a canine model. Photomed Laser Surg. 2005;23(2):172–176
  9. Dougherty TJ, Lawrence G, Kaufman JH, Boyle DG, Wushaupt KR, Goldfarb A. Photoradiation in the treatment of recurrent breast carcinoma. J Natl Cancer Inst. 1979;62:231–237
  10. Figge FHJ, Weiland GS, Manganiello LOJ. Cancer detection and therapy. Affinity of neoplastic and traumatized regenerating tissues for porphyrins and metalloporphyrins. Proc Soc Exp Biol Med. 1948;68:540–641
  11. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64
  12. Gross S, Gilead A, Scherz A, Neeman M, Salomon Y. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med. 2003;9(10):1327–1331
  13. Henderson BW, Fingar VH. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res. 1987;47:3110–3114
  14. Henderson BW, Waldow SM, Mang TS, Dougherty TS. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 1985;45:572–576
  15. Herman MA, Fromm D, Kessel D. Tumor blood-flow changes following protoporphyrin IX based photodynamic therapy in mice and humans. J Photochem Photobiol B. 1999;52(1–3):99–104
  16. His RA, Kapatkin A, Strandberg J, et al. Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res. 2001;7:651–660
  17. Huang Z, Chen Q, Tmcic W, et al. Effects of Pd-bacterio pheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation. Radiat Res. 2004;161(6):723–731
  18. Jankun J, Lilge L, Dauplik A, Keck RW, Pestka M, Szkudlarek M, et al. Optical characteristics of the canine prostate at 665nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy. J Urol. 2004;172:739–743
  19. Kelly JF, Snell ME, Berenbaum ML. Photodynamic destruction of human bladder carcinoma. Br J Cancer. 1975;31:237–244
  20. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol [B]. 1990;6:143–148
  21. Lee LK, Whitehurst C, Chen Q, Pantelides ML, Hetzel FW, Moore JV. Interstitial photodynamic therapy in the canine prostate. Br J Urol. 1997;80:898–902
  22. Lipson RL, Baldes EJ. The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol. 1960;82:508–615
  23. McNeal JE. The prostate and prostatic urethra: a morphologic synthesis. J Urol. 1972;107(6):1008–1016
  24. McPhee MS, Thorndyke CW, Thomas G, Tulip J, Chapman JD, Lahey WH. Interstitial applications of laser irradiation in hematoporphyrin derivative-photosensitized Dunning R3327 prostate cancers. Lasers Surg Med. 1984;4:93–95
  25. Morgan AR, Rampersaud A, Garbo GM, Keck RW, Selman SH. New sensitizers for photodynamic therapy: controlled synthesis of purpurins and their effect on normal tissue. J Med Chem. 1989;32:904–908
  26. Movas B, Chapman JD, Horwitz EM, et al. Hypoxic regions exist in human prostate carcinoma. Urology. 1999;53:11–18
  27. Nathan TR, Whitlaw DE, Chang SC, et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol. 2002;168(October):1427–1432
  28. Onik G. Image-guided prostate cryosurgery: state of the art. Cancer Control. 2001;8(6):522–531
  29. Pantelides ML, Whitehurst C, Moore JV, King TA, Blackhoch NJ. Photodynamic therapy for localized prostatic cancer: light penetration in human prostatic gland. J Urol. 1990;143:398
  30. Rebillard X, Gelet A, Darin JL, et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer. J Endourol. 2005;19(6):693–701
  31. Schreiber S, Gross S, Brandis A, et al. Local photodynamic therapy (PDT) of rat (6 glioma xenografts with Pd-bacteriopheophorbide leads to decreased metastases and increase of annual cure compared to surgery. Int J Cancer. 2002;99(2):279–285
  32. Selman SH, Albrecht D, Keck RW, Brennan P, Kondo S. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate. J Urol. 2001;165:1795–1801
  33. Selman SH, Keck RW, Hampton JA. Transperineal photodynamic ablation of the canine prostate. J Urol. 1996;156:258–260
  34. Selman SH, Kreimer-Birnbaum M, Klaunig JE, Goldblatt PJ, Keck RW, Britton SL. Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. Cancer Res. 1984;44:1924–1927
  35. Star WM, Marijnissen PA, van der Berg-Bok AE, Verstug JA, Franken KAP, Reinhold HS. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in-vivo in sandwich observation chambers. Cancer Res. 1986;46:2532–2540
  36. van den Boogert J, van Staveron HJ, de Bruin RW, Siersema PD, van Hillegersberg R. Fractionated illumination for esophageal ALA-PDT: effect on blood flow and Pp II formation. Lasers Med Surg. 2001;16(1):16–25
  37. Weersink RA, Bogaards A, Gutner M, et al. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B. 2005;79(3):211–222
  38. Whitehurst C, Pantelides ML, Moore JV, Brooman PJC, Blackloch NJ. In vivo laser light distribution in human prostatic carcinoma. J Urol. 1994;151:1411–1415
  39. Windahl T, Anderson SO, Lofgren L. Photodynamic therapy of localized prostate cancer. Lancet. 1990;336:1139
  40. Young SW, Woodburn KW, Wright M, et al. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol. 1996;63:892–897
  41. Zaak D, Stohn R, Hoeppner M. Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer: preliminary results. Med Laser Appl. 2003;18:17–21
  42. Zhu TC, Finlay JC, Hahn SM. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium mediated photodynamic therapy. J Photochem Photobiol B: Biol. 2005;79:231–241

PII: S1572-1000(06)00134-7

doi: 10.1016/j.pdpdt.2006.10.002

Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 1 , Pages 26-30 , March 2007

Article Tools

* Image Usage & Resolution